Johnson & Johnson downgraded by Leerink Partners with a new price target

5/13/25 8:56:13 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Leerink Partners downgraded Johnson & Johnson from Outperform to Market Perform and set a new price target of $153.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$JNJ

Date	Price Target	Rating	Analyst
5/13/2025	$153.00	Outperform → Market Perform	Leerink Partners
12/10/2024	$166.00	Neutral	BofA Securities
11/15/2024	$190.00	Outperform	Wolfe Research
7/23/2024	$160.00 → $150.00	Outperform → Neutral	Daiwa Securities
5/30/2024	$160.00	Neutral	Goldman
4/18/2024	$170.00	Hold → Buy	HSBC Securities
12/13/2023	$170.00 → $163.00	Overweight → Equal Weight	Wells Fargo
12/1/2023	$167.00 → $180.00	Neutral → Buy	UBS